Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Empowering patients to control their diseases with Charles Mattocks

Charles Mattocks is an Award-Winning actor, director, producer, television host and health advocate whose priority for health first and saving lives does not get in his way of excelling in all areas of the business. The nephew of the late great Bob Marley, Mattocks comes from a very high-profile family lineage. His work has been showcased with appearances on CNN, The Today Show, Dr. Oz, Fox News, Good Morning America, The Talk, The Martha Stewart Show and numerous media outlets worldwide.

Clips of his shows can be found below:

Eight days cancer series: https://www.youtube.com/watch?v=rmlHBN3Gfcg

Reversed tv series trailer: https://vimeo.com/224587982

Carnivore tv series trailer: https://www.youtube.com/watch?v=jr4asXbVVoY&t=7s

Our body is thy temple trailer: https://www.youtube.com/watch?v=4eAnhXoRNBg&t=12s

Keto series: https://www.youtube.com/watch?v=aa9LZ9sMDxc&t=7s

Trial by fire trailer: https://vimeo.com/152911789

#charles #mattocks #bob #marley #patient #empowerment #narrative #medicine

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Comments 0

  1. What an eye-opener!
    NED!!!!!!!! Those are the words we want to hear!
    Hallelujah!!!!!!!!

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!